Business Context and Reporting Period
This Form 8-K Current Report was filed by Capstone Holding Corp. (CAPS) on January 7, 2026. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with continued listing standards.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on the Company's stock price performance relative to Nasdaq listing requirements.
Material Changes and Events
- Deficiency Notice: The Company received a deficiency letter from Nasdaq stating that its common stock closing bid price has been below the minimum $1.00 per share requirement for the last 30 consecutive business days.
- Listing Status: The deficiency letter has no immediate effect on the listing; the stock continues to trade on The Nasdaq Capital Market under the symbol "CAPS."
- Compliance Period: The Company has been granted an initial 180 calendar days, until July 6, 2026, to regain compliance.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to monitor the closing bid price and may consider available options to regain compliance. However, management explicitly states there can be no assurance that compliance will be achieved.
Risks and Contingencies:
- Delisting Risk: If the Company fails to regain compliance by July 6, 2026, its securities may be subject to delisting.
- Second Compliance Period: If the initial period expires without compliance, the Company may be eligible for an additional 180-day period, provided it meets the market value of publicly held shares and other initial listing standards (excluding the bid price requirement) and notifies Nasdaq of its intent to cure.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from expectations due to inherent risks and uncertainties.
Investor Verification Checklist
- Verify the current closing bid price of CAPS stock to assess the severity of the deficiency.
- Monitor the Company's announcements regarding any potential reverse stock splits or other corporate actions intended to raise the share price.
- Review the Company's market value of publicly held shares to determine eligibility for a second compliance period if the first deadline is missed.
- Check for subsequent filings between January 7, 2026, and July 6, 2026, regarding the status of the deficiency cure.